LCGC North America Application Note Alert Having trouble viewing this email? Click here Average DAR for Cysteine Conjugates Average DAR is a critical attribute for Antibody-Drug Conjugates (ADCs) and reversed phase LC becoming a preferred route for analysis. Size Exclusion of mAbs and a Well-Salted Buffer The best approach to optimize mobile phase conditions for mAb analysis by SEC. Aggregate Analysis with bioZen SEC Columns bioZen SEC columns were developed with a combination of UHPLC efficiency and higher sensitivity, to drive resolution and identification of even lower level mAb aggregates. N-Glycan Analysis with bioZen 2.6 µm Glycan Methodology starting point when working with mAbs and looking at common fucosylated, neutral biantennary glycans. BioTi: A New Biocompatible Titanium Hardware Hardware and frit that doesn't interfere with protein or peptide integrity and curtails unwanted secondary interactions, problematic carryover, and recovery issues. bioZen LC Column Product Guide Hardware, platforms, particle chemistries, peptide mapping, intact mass, intact and fragment analysis, glycan analysis, peptide quantitation, and drug antibody ratio.